Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

4D Molecular Therapeutics, Inc.

NASDAQ: FDMT · Life Sciences · 6 alerts · CIK 1650648

Share price
$11.29Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All 4D Molecular Therapeutics, Inc. filings on SEC EDGAR ↗

4:19 PM ET 10-Q
Financial Results

4D Molecular Therapeutics Q3 2026 Results: Net Loss of $78.1M, Loss Widens

4D Molecular Therapeutics is a clinical-stage genetic medicine company reporting 56,379,402 shares of common stock outstanding as of November 9, 2026. The company continues to incur significant net losses and requires substantial additional capital to fund the development of its lead AAV product candidates, including 4D-150 and 4D-175.

Key figure
Net loss $78.1M
4:12 PM ET 8-K
Financial Results

4D Molecular Therapeutics Financial Results

4D Molecular Therapeutics reported Q3 2026 financial results and provided updates on its 4D-150 clinical programs, including the completion of randomization for the 4FRONT-2 Phase 3 trial in wet AMD. The company ended the quarter with $375 million in cash, which is expected to fund operations into the second half of 2028.

“Over the past quarter, 4DMT continued to progress 4D-150 as a potential backbone therapy for continuous control of VEGF-driven retinal diseases through completion of randomization in the second of two pivotal Phase 3 trials in wet AMD.”

David Kirn, MD, Co-founder, President and Chief Executive Officer
4:56 PM ET Form 4
Insider Selling

4D Molecular Therapeutics CLO Scott Bizily Sells $21K of Stock

Scott Bizily, CLO, sold 1,635 shares of 4D Molecular Therapeutics, Inc. at $12.84 a share, worth $21K in total on Oct 16, 2026. Shares held after the trade: 8,617 (-15.9%).

Value
$21K
Shares
1,635
Price
$12.84
Role
CLO
Holding change
-15.9%
Trade date
Oct 16, 2026
5:12 PM ET Form 4
Insider Selling

4D Molecular Therapeutics Insider David Kirn Sells $750K of Stock

David Kirn sold 58,061 shares of 4D Molecular Therapeutics, Inc. at $12.92 a share, worth $750K in total on Oct 5, 2026. Shares held after the trade: 709,425 (-7.6%).

Value
$750K
Shares
58,061
Price
$12.92
Holding change
-7.6%
Trade date
Oct 5, 2026
8:06 AM ET 8-K
Clinical Trial Data

4D Molecular Therapeutics Clinical Trial Data

4D Molecular Therapeutics announced the enrollment of the first patients in its 4SIGHT Phase 3 clinical trial evaluating 4D-150 for diabetic macular edema (DME). The company also released positive 2-year data from its SPECTRA clinical trial, showing 4D-150 was well tolerated with a 61% reduction in treatment burden compared to standard aflibercept injections.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.